Ces Urol X:X | DOI: 10.48095/cccu2026004
Combination of systemic and surgical treatment in a patient with primarily inoperable renal cell carcinoma in a horseshoe kidney: the importance of multidisciplinary collaboration – updated results of 3-year follow-up
- 1 Urologická klinika LF UP a FN Olomouc
- 2 Onkologická klinika LF UP a FN Olomouc
Primarily inoperable, locally advanced renal cell carcinoma represents a significant challenge in uro-oncology. Although systemic therapy is not a standard component of treatment in this setting, in carefully selected patients it may lead to disease regression and enable subsequent surgical resection. We present updated results of a 3-year follow-up of a patient with an initially inoperable finding in whom systemic therapy created the conditions for a subsequent successful surgical intervention.
Keywords: renal cell carcinoma – systemic therapy – regression – surgical management
Received: December 11, 2025; Revised: February 2, 2026; Accepted: February 7, 2026; Prepublished online: March 3, 2026
References
- Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229-263. doi: 10.3322/caac.21834.
Go to original source... 
Go to PubMed... - International Agency for Research on Cancer. GLOBOCAN 2020: Cancer today - kidney cancer internet. Lyon: IARC 2020. [online]. Available from: https://gco.iarc.who.int/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf.
- EAU Guidelines. Edn. presented at the EAU EAU Guidelines, Madrid 2025. [online]. Available from: https://uroweb.org/guidelines/renal-cell-carcinoma.
- Bindayi A, Hamilton ZA, McDonald ML et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol 2018; 36(1): 31-37. doi: 10.1016/j.urolonc.2017.07.015. Go to original source... Go to PubMed...
- Zemankova A, Studentova H, Kopova A et al. Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney - how to achieve a safe and radical resection? A case report and review of the literature. Front Oncol 2023; 13: 1115901. doi: 10.3389/fonc.2023.1115901. Go to original source... Go to PubMed...
- Bilen MA, Jiang JF, Jansen CS et al. Neoadjuvant cabozantinib in an unresectable locally advanced renal cell carcinoma patient leads to downsizing of tumor enabling surgical resection: a case report. Front Oncol 2021; 10: 622134. doi: 10.3389/fonc.2020.622134. Go to original source... Go to PubMed...
- Roy AM, Briggler A, Tippit D et al. Neoadjuvant cabozantinib in renal-cell carcinoma: a brief review. Clin Genitourin Cancer 2020; 18(6): e688-e691. doi: 10.1016/j.clgc.2020.04.003. Go to original source... Go to PubMed...
- Ingels A, Campi R, Capitanio U et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022; 19(7): 391-418. doi: 10.1038/s41585-022-00592-3. Go to original source... Go to PubMed...
- Roussel E, Tasso G, Campi R et al. Surgical management and outcomes of renal tumors arising from horseshoe kidneys: results from an international multicenter collaboration. Eur Urol 2021; 79(1): 133-140. doi: 10.1016/j.eururo.2020.09.012. Go to original source... Go to PubMed...
- European Association of Urology. EAU Guidelines on Renal Cell Carcinoma 2024. [online]. Available from: https://uroweb.org/guidelines/renal-cell-carcinoma.
- Bex A, Jewett M, Lewis B et al. A call for a neoadjuvant kidney cancer consortium: lessons learned from other cancer types. Eur Urol 2025; 87(4): 385-389. doi: 10.1016/j.eururo.2025.01.007. Go to original source... Go to PubMed...
- Allaf ME, Kim SE, Master V et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024; 25(8): 1038-1052. doi: 10.1016/S1470-2045(24)00211-0. Go to original source... Go to PubMed...
- Motzer RJ, Rini BI, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20(10): 1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Go to original source... Go to PubMed...